Razi Cov Pars (Persian: رازی کوو پارس) is a COVID-19 vaccine developed by the Iranian Razi Vaccine and Serum Research Institute Razi Cov Pars is a covid-19 vaccine based on recombinant protein, which is being produced by Razi Vaccine and Serum Research Institute, Iran. This vaccine is the first injectable-intranasal recombinant protein corona vaccine.It's the second Iranian COVID-19 vaccine reaching human trials and is currently in phase III of clinical research during which it's compared to the Sinopharm BIBP vaccine. 


== Medical uses ==
It requires three doses given day 0 (intramuscular), day 21 (intramuscular) and day 51 (intranasal spray).


== Pharmacology ==
Razi Cov Pars is a recombinant protein subunit vaccine containing the SARS-CoV-2 spike protein.


== Manufacturing ==
It's planned to produce one million doses of the vaccine each month as of September 2021.
As of 25 November 2021, 5 millions doses have been delivered to the Iranian Ministry of Health.


== History ==


=== Clinical trials ===


== See also ==
Pharmaceuticals in Iran
COVID-19 pandemic in Iran
COVID-19 vaccine clinical research


== References ==


== Further reading ==